The Analyst Verdict: Inovio Pharmaceuticals In The Eyes Of 4 Experts
Portfolio Pulse from Benzinga Insights
Inovio Pharmaceuticals (NASDAQ:INO) has received mixed analyst ratings over the past three months, with a recent average price target of $15.75, down from $18.50. Analysts have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Inovio faces financial challenges, including a significant revenue decline and below-average profitability metrics.
October 04, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Inovio Pharmaceuticals has received mixed analyst ratings, with a recent average price target of $15.75, down from $18.50. Analysts have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. The company faces financial challenges, including a significant revenue decline and below-average profitability metrics.
The mixed analyst ratings and lowered price targets indicate a bearish sentiment towards Inovio Pharmaceuticals. The company's financial challenges, such as declining revenue and poor profitability metrics, further support a negative short-term outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100